Cannabis Law Report

OCTOBER 4, 2021

Accordingly, it cannot be prescribed by a physician and it is not legally accessible to those who might benefit from it as a therapeutic treatment. Access Pursuant to the Oregon Psilocybin Services Act. The shelter provided by this approach depends on the policy of the U.S. Source: [link].

Therapy 52

Therapy Patients Law Clinical Trials 52

Cannabis Law Report

JULY 7, 2021

Pennington, who focuses on federal appeals and regulatory issues, is co-counsel on several high-profile cases against the DEA regarding cannabis research, hemp, and psychedelics. Circuit), a pending petition for review of DEA’s August 2020 Interim Final Rule purportedly implementing the 2018 Farm Bill’s amendments to the CSA.

DEA 111

DEA Hemp Cultivation Advocacy 111

Cannabis Law Report

JULY 1, 2021

The Project on Psychedelics Law and Regulation at the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School will advance evidence-based psychedelics law and policy. Mason Marks: The project’s goal is to promote safety, innovation, equity, and accessibility in emerging psychedelics industries.

Law 105

Law Research and Development Therapy DEA 105

Cannabis Law Report

MAY 29, 2022

Widespread approval for psychedelic treatments remains unlikely, but the tide is slowly turning. In 2019, FDA approved Spravato (esketamine) nasal spray for treatment of depression in adults. [8] 8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. Defining Psychedelics.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Canna Law Blog

MARCH 4, 2020

People are increasingly using ketamine for ailments that resist treatment through traditional pharmaceutical drugs. From 2015 to 2018, the number of clinics increased from 60 to 300; that number is undoubtedly higher today. Failure to follow these very specific legal directives can lead to immediate criminal liability under federal law.

Therapy 90

Therapy Legalization Chronic Pain DEA 90

CannaMD

SEPTEMBER 15, 2020

SHORT ANSWER: In November 2016, the Florida Medical Marijuana Legalization Initiative (known as Amendment 2 ) legalized medical marijuana treatment in Florida. In March, 2016, State Bill 307 expanded access to full-strength medical marijuana to terminally ill patients who were determined by two doctors to have less than a year to live.

Law 126

Law Marijuana Patients Treatment 126

Veriheal

AUGUST 24, 2022

This campaign was backed by New Approach PAC, a nationwide political organization that is focused on supporting progressive reform surrounding cannabis and criminal justice policies. In May 2022, Connecticut’s governor signed a budget bill that included a provision for the implementation of psychedelic-assisted therapy treatment centers.

Legalization 108

Legalization Medicine Decriminalization Research and Development 108

Veriheal

NOVEMBER 11, 2023

According to the United States Drug Enforcement Administration (DEA), Schedule One drugs are “drugs with no currently accepted medical use and a high potential for abuse.” Nonetheless, with the increasing legalization of medical cannabis, many veterans and interest groups have asked the government to change its policies.

Law 62

Law Chronic Pain Conditions Legislation 62

Burns Levinson (Cannabusiness advisory)

OCTOBER 3, 2018

This marks the first time in history that the DEA has removed any type of cannabis from Schedule I, and clears the way for the sale of the first non-synthetic, cannabis-derived medicine to win federal approval. According to the DEA order, because the drug was recently approved by the FDA, it is now considered to have an accepted medical use.

CBD 40

CBD DEA Epilepsy Pharmaceutical 40

Cannabis Law Report

APRIL 8, 2022

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. Later that year, Doblin sued the DEA for the first time. Lyle Craker, Ph.D.,

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

AUGUST 12, 2022

Drug policy topics have become a consistent feature of the Austin-based event in recent years as more states have legalized cannabis and moved to reform laws around psychedelics like psilocybin locally and at the state level. The panel would center on the evolution of cannabis policy in the U.S.,

Research and Development 52

Research and Development Events Topical Policy 52

Cannabis Law Report

SEPTEMBER 1, 2021

While there has been increasing attention and interest in this issue on Capitol Hill, in the near term the federal tax treatment of cannabis-related business remains fraught with risks. 12] Ultimately, only Congress can amend the CSA itself to remove, or otherwise reform the treatment of cannabis under federal law.

Policy 100

Policy Cannabis Treatment Law 100

Cannabis Law Report

JUNE 15, 2021

. – Today, ahead of the 50th anniversary—on June 17—of when President Richard Nixon declared the “war on drugs,” Representatives Bonnie Watson Coleman (D-NJ) and Cori Bush (D-MO) unveiled the Drug Policy Reform Act (DPRA), alongside the Drug Policy Alliance, which has been a strategic partner on the development of the legislation.

Decriminalization 78

Decriminalization Policy Research and Development Data 78

Canna Law Blog

NOVEMBER 16, 2021

The enforcement role moves from DEA to ATF. When it comes to enforcing federal cannabis regulations, the Drug Enforcement Administration (“DEA”) is out and the Bureau of Alcohol, Tobacco, Firearms, and Explosives (“ATF”) is in (in addition to TTB as the primary overseer). ” SBA fairness.

DEA 88

DEA Business Banking Food 88

Veriheal

DECEMBER 27, 2022

Researchers have taken a big step in understanding the connection between using psychedelics and feeling connected to nature in a study published in the journal Drug Science, Policy, and Law on Oct. Study findings indicated that those who had previously taken LSD and psilocybin reported a greater sense of “nature relatedness.”

Research and Development 95

Research and Development Therapy Consumption DEA 95

Cannabis Law Report

JANUARY 14, 2020

CLICK IMAGE TO ACCESS COMMITTEE INFO PAGE. Senior Policy Advisor, Diversion Control Division. Amidst growing evidence that marijuana can be used to effectively treat post-traumatic stress disorder , this bill from California Democrat Barbara Lee focuses on greatly expanding access to medical marijuana for veterans. Legislation.

Clinical Trials 69

Clinical Trials Programs Access DEA 69

Cannabis Law Report

FEBRUARY 28, 2022

Importantly, control of psychedelics by a small number of companies may stifle innovation and reduce access to these therapies. 1025, 1026 (2021) (reporting significant improvement of PTSD symptoms following treatment with MDMA in clinical trial); see also Alec J. Mitchell et al., Divito & Robert F. TIMES (Nov. Feduccia et al.,

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

Cannabis Law Report

MAY 24, 2022

The criminalization of marijuana was the result of racially motivated policies, such as the Marijuana Tax Act of 1937. Ronald Reagan continued this frontline war in 1981 by expanding the reach of the war and shifting his focus on ensuring criminal punishment over treatment ultimately leading to mass incarceration for nonviolent drug offenses.

DEA 52

DEA History Medicine Marijuana 52

Cannabis Law Report

SEPTEMBER 23, 2019

The AAFP urges its members to be involved in the diagnosis, treatment, and prevention of substance use, as well as secondary diseases impacted or caused by use. During the 20 th century, law enforcement and public policy activities have undermined opportunities for scientific exploration. Relevant AAFP Policy. Call to Action.

Cannabinoids 40

Cannabinoids Marijuana Research and Development Access 40

Kind Meds (Cannabis Education Blog)

FEBRUARY 7, 2022

As policies become more data-driven and progressive, cultivation and production technologies have continued to improve drastically over the past several years. The DEA still classifies cannabis as a Schedule I controlled substance, a designation reserved for drugs with no medical value and a high potential for abuse.

Recreational 52

Recreational Data Cannabis DEA 52

The Cannigma

SEPTEMBER 12, 2021

This contradiction, combined with a problematic regulatory framework that limits access to THC products in many states, has created a booming market for d-8 and d-10. Depending on the state you’re in, THC products may be legally accessible to any adult, and other states restrict access to medical patients only. THC vs CBD.

THC 98

THC Research and Development Cannabinoids CBD 98

Cannabis Law Report

JULY 14, 2021

Legislation opens doors for cannabis policy reform in the current Congress. Cory Booker (D-NJ) and Ron Wyden (D-OR), released draft legislation today that would remove cannabis from the schedule of controlled substances while allowing states to determine their own cannabis policies. WASHINGTON, D.C. But this alone is not enough.

Legislation 71

Legislation Banking History Access 71

SpeedWeed

MARCH 18, 2021

Preliminary results from a long-awaited study indicate that cannabis appears to be a safe and well-tolerated treatment for patients managing post-traumatic stress disorder (PTSD), although researchers did not find strong signals of effectiveness. Wasn’t the DEA going to let others grow research-grade cannabis? It tested at only 9% THC.

Clinical Trials 40

Clinical Trials THC Strains Cannabis 40

Cannabis Law Report

JULY 30, 2019

Like others, Dr. Beasley is forced by default to expand her knowledge base through scientific facts that warrant closer inspection and through accessible existing research, with few current cannabis case studies. Cannabis is not a “gateway” drug, according to the ASA and the DEA’s own statements cited in the August 2016 U.S.

Marijuana 45

Marijuana Patients Research and Development Programs 45

The Cannigma

FEBRUARY 16, 2022

Listen & Subscribe: In light of Black History Month, we feel it is important and relevant to talk about how minorities in the United States and around the world have been disproportionately affected by drug policy and the war on drugs. We always have a nice little tidbit when we’re all about advocacy and access to cannabis for all.

Trichome 73

Trichome Wellness and Beauty Cannabinoids Cannabis 73

SpeedWeed

DECEMBER 28, 2018

Bummer: Patients Are Still Struggling for Cannabis Access. RELATED STORY. 6 International Cannabis Strains Worth Seeking Abroad. John Flickner, a 78-year-old resident of Niagara Falls, New York, was evicted from his federally subsidized housing in December of this year for using a vape pen.

Pharmaceutical 40

Pharmaceutical Research and Development Legalization CBD 40